Home › Funds › Soleus Capital Management, L.P. › RIGL

Soleus Capital Management, L.P. position in RIGL

RIGEL PHARMACEUTICALS INC · Health Care

Soleus Capital Management, L.P. reported holding 1,843,504 shares of RIGL (RIGEL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$72.1M, representing 2.49% of its reported portfolio and ranking #8 among its reported holdings. Soleus Capital Management, L.P. has disclosed RIGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.84M sh
Reported value held$72.12M
Portfolio Weight2.49%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s RIGL position evolved

Soleus Capital Management, L.P. first disclosed a stake in RIGL in Q3 2023 at 14,803,015 shares (US$16.0M). The position peaked in Q2 2026 at 1,843,504 shares, worth US$72.1M. Across 12 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 8 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,843,504 shares valued at US$72.1M — an increase of 1,833,504 shares quarter over quarter.. Notable position changes include a 89% trim in Q2 2024 (shares rose 97% over the following quarter), a 97% trim in Q1 2026 (shares rose 45% over the following quarter), a 18335% increase in Q2 2026 (shares rose 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 14.80M $15.99M New
Q4 2023 9.44M $13.69M Reduce
Q1 2024 9.24M $13.68M Reduce
Q2 2024 1.04M $8.58M Reduce
Q3 2024 934.79K $15.12M Reduce
Q4 2024 1.13M $19.02M Add
Q1 2025 1.13M $20.34M Hold
Q2 2025 658.14K $12.33M Reduce
Q3 2025 330.01K $9.35M Reduce
Q4 2025 300.03K $12.85M Reduce
Q1 2026 10.00K $270.40K Reduce
Q2 2026 1.84M $72.12M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About RIGL and 13F data

RIGL (RIGEL PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in RIGL — the largest reported positions include ARMISTICE CAPITAL, LLC (US$65.4M), CM Management, LLC (US$9.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding RIGL

All RIGL fund holders →

FAQ

How long has Soleus Capital Management, L.P. held RIGL?

Soleus Capital Management, L.P. has disclosed RIGL holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in RIGL?

As of Q2 2026, Soleus Capital Management, L.P. holds 1.84M shares of RIGL (RIGEL PHARMACEUTICALS INC), valued at $72.12M, representing 2.49% of its reported portfolio and ranking #8.

Has Soleus Capital Management, L.P. been buying or selling RIGL?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in RIGL. The position peaked in Q2 2026 at 1.84M shares.

Which other funds hold RIGL?

Other major institutional holders of RIGL include ARMISTICE CAPITAL, LLC, CM Management, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.